Patents by Inventor Sufi Mary Thomas

Sufi Mary Thomas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense EGFRAS guanidinium peptide nucleic acid (GPNA) oligonucleotides as antitumor agents
    Patent number: 9334496
    Abstract: A class of antisense agents having a distributed guanidinium peptide nucleic acids (GPNA) backbone which has excellent uptake into mammalian cells, can bind to the target DNA or RNA in a highly sequence specific manner and can resist nucleases and proteases both outside and inside the cell(s) of interest. In one embodiment, either systemic or intratumoral administration of antisense Epidermal Growth Factor Receptor (“EGFR”) GPNA oligonucleotides is believed to downmodulate EGFR levels, thus in turn to reduce head and neck squamous cell carcinoma tumor growth, which has been confirmed to date both in vitro and in vivo.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: May 10, 2016
    Assignees: EYE & EAR FOUNDATION, UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, CARNEGIE MELLON UNIVERSITY
    Inventors: Jennifer Rubin Grandis, Sufi Mary Thomas, Danith H. Ly
  • Antisense EGFRAS Guanidinium Peptide Nucleic Acid (GPNA) Oligonucleotides as Antitumor Agents
    Publication number: 20110306562
    Abstract: A class of antisense agents having a distributed guanidinium peptide nucleic acids (GPNA) backbone which has excellent uptake into mammalian cells, can bind to the target DNA or RNA in a highly sequence specific manner and can resist nucleases and proteases both outside and inside the cell(s) of interest. In one embodiment, either systemic or intratumoral administration of antisense Epidermal Growth Factor Receptor (“EGFR”) GPNA oligonucleotides is believed to downmodulate EGFR levels, thus in turn to reduce head and neck squamous cell carcinoma tumor growth, which has been confirmed to date both in vitro and in vivo.
    Type: Application
    Filed: May 13, 2011
    Publication date: December 15, 2011
    Inventors: Jennifer Rubin Grandis, Sufi Mary Thomas, Danith H. Ly
  • Antisense guanidinium peptide nucleic acid (GPNA) oligonucleotides as antitumor agents
    Patent number: 7960360
    Abstract: A class of antisense agents having a distributed guanidinium peptide nucleic acids (GPNA) backbone which has excellent uptake into mammalian cells, can bind to the target DNA or RNA in a highly sequence specific manner and can resist nucleases and proteases both outside and inside the cell(s) of interest. In one embodiment, either systemic or intratumoral administration of antisense Epidermal Growth Factor Receptor (“EGFR”) GPNA oligonucleotides is believed to downmodulate EGFR levels, thus in turn to reduce head and neck squamous cell carcinoma tumor growth, which has been confirmed to date both in vitro and in vivo.
    Type: Grant
    Filed: November 13, 2007
    Date of Patent: June 14, 2011
    Inventors: Jennifer Rubin Grandis, Sufi Mary Thomas, Danith H. Ly
  • ANTISENSE GUANIDINIUM PEPTIDE NUCLEIC ACID (GPNA) OLIGONUCLEOTIDES AS ANTITUMOR AGENTS
    Publication number: 20080234181
    Abstract: A class of antisense agents having a distributed guanidinium peptide nucleic acids (GPNA) backbone which has excellent uptake into mammalian cells, can bind to the target DNA or RNA in a highly sequence specific manner and can resist nucleases and proteases both outside and inside the cell(s) of interest. In one embodiment, either systemic or intratumoral administration of antisense Epidermal Growth Factor Receptor (“EGFR”) GPNA oligonucleotides is believed to downmodulate EGFR levels, thus in turn to reduce head and neck squamous cell carcinoma tumor growth, which has been confirmed to date both in vitro and in vivo.
    Type: Application
    Filed: November 13, 2007
    Publication date: September 25, 2008
    Inventors: Jennifer Rubin GRANDIS, Sufi Mary THOMAS, Danith H. LY